SCHEMBL1764183

SCHEMBL1764183

CC(NC(=O)C(Cc1ccc(-c2ccccc2)cc1)CP(=O)(O)C(NC(=O)OCc1ccccc1)c1ccsc1)C(=O)O

nearest known ligand 0.64

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MME P08473 12/20 0.64
ECE1 P42892 10/20 0.64
ANPEP P15144 2/20 0.60
ACE P12821 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1764688 0.94 MME (0.56) MMEECE1ANPEP
SCHEMBL1764690 0.94 MME (0.56) MMEECE1ANPEP
SCHEMBL1764692 0.94 MME (0.56) MMEECE1ANPEP
SCHEMBL12596629 0.88 MME (0.58) MMEECE1ANPEP
SCHEMBL1764177 0.88 MME (0.58) MMEECE1ANPEP
SCHEMBL6922969 0.84 ECE1 (0.91) MMEECE1ACE
SCHEMBL12596623 0.82 MME (0.56) MMEECE1ANPEP
SCHEMBL1764396 0.82 MME (0.56) MMEECE1ANPEP
SCHEMBL7611034 0.81 MME (0.67) MMEECE1ANPEP
SCHEMBL7719798 0.81 MME (0.67) MMEECE1ANPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10131681-B2 Aminophosphinic derivatives that can be used in the treatment of pain PHARMALEADS (FR) 2018-11-20 US disclosed
US-20140161839-A1 AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN PHARMALEADS (FR) 2014-06-12 US disclosed
US-8703747-B2 Aminophosphinic derivatives that can be used in the treatment of pain PHARMALEADS (FR) 2014-04-22 US disclosed
US-20110124601-A1 AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN PHARMALEADS 2011-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124601-A1 AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN OPRM1, HRH3, HRH4 MME 3670/4885ECE1 4157/4885ANPEP 2038/4885
US-10131681-B2 Aminophosphinic derivatives that can be used in the treatment of pain OPRM1, HRH3, HRH4 MME 3490/4885ECE1 4097/4885ANPEP 2062/4885
US-20140161839-A1 AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN OPRM1, HRH3, HRH4 MME 3490/4885ECE1 4097/4885ANPEP 2062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.